1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Radiopharmaceutical Theranostics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Radiopharmaceutical Theranostics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1
- 5.1.2 Rising prevalence of cancer and other chronic diseases drives demand for targeted radiopharmaceutical therapies.
- 5.1.3 Technological advancements in imaging and therapy techniques enhance the efficacy of theranostic approaches.
- 5.1.4 Growing emphasis on personalized medicine promotes the adoption of radiopharmaceutical theranostics.
5.2 Market Opportunities
- 5.2.1
- 5.2.2 Expansion of research and development activities in radiopharmaceuticals offers significant growth potential.
- 5.2.3 Increasing collaboration between pharmaceutical companies and research institutions can accelerate product development.
- 5.2.4 Opportunities for novel combinations of imaging agents and therapeutic radiopharmaceuticals to enhance treatment outcomes.
5.3 Future Trends
- 5.3.1
- 5.3.2 Growing focus on integrating radiopharmaceuticals with advanced imaging technologies for improved diagnostic accuracy.
- 5.3.3 increased emphasis on developing novel theranostic agents tailored to specific patient profiles and tumor types.
- 5.3.4 Advancements in regulatory frameworks for radiopharmaceuticals may streamline approval processes and market entry.
5.4 Impact of Drivers and Restraints
6. North America Radiopharmaceutical Theranostics Market Regional Analysis
6.1 North America Radiopharmaceutical Theranostics Market Overview
6.2 North America Radiopharmaceutical Theranostics Market Revenue 2020-2028 (US$ Million)
6.3 North America Radiopharmaceutical Theranostics Market Forecast Analysis
7. North America Radiopharmaceutical Theranostics Market Analysis – by Product Type
7.1 Alpha Emitters
- 7.1.1 Overview
- 7.1.2 Alpha Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Beta Emitters
- 7.2.1 Overview
- 7.2.2 Beta Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Positron Emission Tomography Tracers
- 7.3.1 Overview
- 7.3.2 Positron Emission Tomography Tracers: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Radiopharmaceutical Theranostics Market Analysis – by Radioisotope
8.1 Technetium-99
- 8.1.1 Overview
- 8.1.2 Technetium-99: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Gallium-68
- 8.2.1 Overview
- 8.2.2 Gallium-68: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Iodine-131
- 8.3.1 Overview
- 8.3.2 Iodine-131: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Iodine-123
- 8.4.1 Overview
- 8.4.2 Iodine-123: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Fluorine-18
- 8.5.1 Overview
- 8.5.2 Fluorine-18: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Yttrium 90
- 8.6.1 Overview
- 8.6.2 Yttrium 90: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Lutetium 177
- 8.7.1 Overview
- 8.7.2 Lutetium 177: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Copper 67
- 8.8.1 Overview
- 8.8.2 Copper 67: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Copper 64
- 8.9.1 Overview
- 8.9.2 Copper 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Radiopharmaceutical Theranostics Market Analysis – by Source
9.1 Nuclear Reactors and Cyclotrons
- 9.1.1 Overview
- 9.1.2 Copper 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
10. North America Radiopharmaceutical Theranostics Market – North America Analysis
10.1 North America
- 10.1.1 North America Radiopharmaceutical Theranostics Market Breakdown, by Key
Country, 2023 and 2028 (%)
- 10.1.1.1 North America Radiopharmaceutical Theranostics Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.1.1 US: North America Radiopharmaceutical Theranostics Market Breakdown, by Product Type
- 10.1.1.1.2 US: North America Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
- 10.1.1.1.3 US: North America Radiopharmaceutical Theranostics Market Breakdown, by Source
- 10.1.1.2 Canada:
North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.2.1 Canada: North America Radiopharmaceutical Theranostics Market Breakdown, by Product Type
- 10.1.1.2.2 Canada: North America Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
- 10.1.1.2.3 Canada: North America Radiopharmaceutical Theranostics Market Breakdown, by Source
- 10.1.1.3 Mexico :
North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
- 10.1.1.3.1 Mexico : North America Radiopharmaceutical Theranostics Market Breakdown, by Product Type
- 10.1.1.3.2 Mexico : North America Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
- 10.1.1.3.3 Mexico : North America Radiopharmaceutical Theranostics Market Breakdown, by Source
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Radiopharmaceutical Theranostics Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Bayer AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GE Healthcare Technologies Inc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Curium
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Lantheus Medical Imaging, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Telix Pharmaceuticals Ltd.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Cardinal Health Inc.
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Advanced Accelerator Applications S.A
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Jubilant Radiopharma
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Theragnostics
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 NuView Life Sciences
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights